Celera

Celera is a biotechnology company focused on providing advanced genomic data and analysis services to enhance health outcomes and research initiatives. Celera is a biotechnology firm that specializes in genomic data analysis and services. The company was founded by Carlos Augier and is headquartered in Alameda, US. In June 2000, Celera filled for an IPO, marking a significant pivot in its business strategy.

The company has been involved in two total deals since its inception. Celera offers a range of genomic analysis services, specializing in the provision of genomic data for healthcare applications and research purposes. Their services cater to both individual researchers and healthcare organizations, enabling enhanced insights into genetic information. Celera's products play a critical role in advancing personalized medicine and improving health-related outcomes through data-driven solutions.

In 2010, Celera reported a revenue of USD 128. 17 mn, with an EBITDA of USD -18. 76 mn for the same year. This demonstrates the company's sustained operations in the genomic sector, although with negative EBITDA.

Moving forward, Celera plans to expand its product line with new genomic services aimed at improving research capabilities in personalized medicine, with projected launches expected in the upcoming fiscal year. The company is also targeting expansion into new geographic markets, particularly in Europe and Asia, in the next two years. The funding raised during its IPO in June 2000 will be utilized to support these initiatives, allowing Celera to enhance its research capabilities and broaden its service offerings.